• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

第四代胃肠外头孢菌素的组织穿透性。

Tissue penetration of the fourth generation parenteral cephalosporins.

作者信息

Wise R

机构信息

City Hospital, NHS Trust, Birmingham, England.

出版信息

J Chemother. 1996 Feb;8 Suppl 2:63-70.

PMID:8738848
Abstract

In this review, the methods employed to study tissue penetration are discussed. Mathematical, animal and human models all have their positive and negative features, however studies in man must be central to studying the pharmacokinetics of these agents. The newly introduced parenteral cephalosporins (cefpirome, cefepime and cefoselis) have been studied in man. In general they penetrate tissues to similar extents to other beta-lactam agents. Non-specialised tissues such as inflammatory exudate and peritoneal fluid are rapidly and extensively penetrated. More specialised tissues (such as prostate) are penetrated to a moderate extent (30 to 50%). Certain sites - such as the CSF - are poorly penetrated (c. 5 to 10%). It is important to have a knowledge of this information prior to therapeutic trials of such agents.

摘要

在本综述中,讨论了用于研究组织穿透性的方法。数学模型、动物模型和人体模型都有其优缺点,然而人体研究对于这些药物的药代动力学研究至关重要。新引入的肠外头孢菌素(头孢匹罗、头孢吡肟和头孢噻利)已在人体中进行了研究。总体而言,它们在组织中的穿透程度与其他β-内酰胺类药物相似。非特异性组织,如炎性渗出液和腹膜液,能被快速且广泛地穿透。更具特异性的组织(如前列腺)的穿透程度适中(30%至50%)。某些部位,如脑脊液,穿透性较差(约5%至10%)。在对此类药物进行治疗试验之前,了解这些信息很重要。

相似文献

1
Tissue penetration of the fourth generation parenteral cephalosporins.第四代胃肠外头孢菌素的组织穿透性。
J Chemother. 1996 Feb;8 Suppl 2:63-70.
2
In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review.头孢曲松与第三代和第四代头孢菌素相比的体外活性、药代动力学、临床疗效、安全性及药物经济学:综述
J Chemother. 2005 Feb;17(1):3-24.
3
Diffusion of 3-quaternary ammonium cephem antibiotics into cerebrospinal fluid of patients with bacterial meningitis.3-季铵头孢菌素类抗生素在细菌性脑膜炎患者脑脊液中的扩散。
J Chemother. 1996 Feb;8 Suppl 2:83-90.
4
Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis.头孢匹罗在脓毒症患者中的血浆和组织药代动力学
Crit Care Med. 2002 Jul;30(7):1478-82. doi: 10.1097/00003246-200207000-00013.
5
Distribution of ceftazidime in rat tissues.头孢他啶在大鼠组织中的分布。
Biopharm Drug Dispos. 1998 Oct;19(7):473-8. doi: 10.1002/(sici)1099-081x(199810)19:7<473::aid-bdd125>3.0.co;2-m.
6
Abscess penetration of cefpirome: concentrations and simulated pharmacokinetic profiles in pus.头孢吡肟脓肿穿透:脓液中的浓度和模拟药代动力学特征。
Eur J Clin Pharmacol. 2012 Oct;68(10):1419-23. doi: 10.1007/s00228-012-1270-1. Epub 2012 Mar 23.
7
Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).针对儿科患者分离出的细菌进行的肠外广谱头孢菌素比较:哨兵抗菌监测计划(1998 - 2004年)报告
Diagn Microbiol Infect Dis. 2007 Jan;57(1):109-16. doi: 10.1016/j.diagmicrobio.2006.06.011. Epub 2006 Aug 23.
8
Fourth generation cephalosporins in the antimicrobial chemotherapy of surgical infections.
J Chemother. 1999 Dec;11(6):486-93. doi: 10.1179/joc.1999.11.6.486.
9
Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin.
Chemotherapy. 2005 May;51(2-3):80-5. doi: 10.1159/000085614. Epub 2005 May 4.
10
Pharmacokinetics, intramuscular bioavailability and tissue residue profiles of ceftazidime in a rabbit model.头孢他啶在兔模型中的药代动力学、肌肉注射生物利用度及组织残留情况
Dtsch Tierarztl Wochenschr. 2001 Apr;108(4):168-71.

引用本文的文献

1
Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.胃肠外头孢菌素类药物的药理学特性:门诊使用的理论依据。
Drugs. 2000;59 Suppl 3:9-18; discussion 47-9. doi: 10.2165/00003495-200059003-00002.
2
Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.头孢匹罗。关于其抗菌活性、药代动力学特性及治疗严重医院感染和发热性中性粒细胞减少症临床疗效的综述。
Drugs. 1997 Jul;54(1):117-40. doi: 10.2165/00003495-199754010-00013.